Enliven Therapeutics (NASDAQ:ELVN) vs. Phibro Animal Health (NASDAQ:PAHC) Head-To-Head Survey

Phibro Animal Health (NASDAQ:PAHC) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends.

Insider & Institutional Ownership

99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by company insiders. Comparatively, 29.2% of Enliven Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Phibro Animal Health and Enliven Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	0.24%	18.08%	4.97%
Enliven Therapeutics	N/A	-29.31%	-27.25%

Analyst Recommendations

This is a breakdown of recent recommendations for Phibro Animal Health and Enliven Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	3	2	0	0	1.40
Enliven Therapeutics	0	0	3	1	3.25

Phibro Animal Health presently has a consensus target price of $15.00, suggesting a potential downside of 35.98%. Enliven Therapeutics has a consensus target price of $34.33, suggesting a potential upside of 19.17%. Given Enliven Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Enliven Therapeutics is more favorable than Phibro Animal Health.

Risk & Volatility

Phibro Animal Health has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.

Valuation and Earnings

This table compares Phibro Animal Health and Enliven Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.02 billion	0.93	$2.42 million	$0.06	390.57
Enliven Therapeutics	N/A	N/A	-$71.58 million	($1.93)	-14.93

Phibro Animal Health has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Summary

Phibro Animal Health beats Enliven Therapeutics on 8 of the 13 factors compared between the two stocks.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal’s health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock’s diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.